Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck May Consider Settling Some Vioxx Suits

This article was originally published in The Pink Sheet Daily

Executive Summary

Representing a shift in legal strategy, Merck may re-evaluate cases involving patients who took Vioxx for long periods of time and had few risk factors for heart disease.

You may also be interested in...



Merck May Need To Rethink Vioxx Defense Strategy Following Surprise Loss

Firm is hit with $31 mil. fine in death of man with many risk factors who took rofecoxib for one week.

Merck May Need To Rethink Vioxx Defense Strategy Following Surprise Loss

Firm is hit with $31 mil. fine in death of man with many risk factors who took rofecoxib for one week.

Merck Cleared In Second Vioxx Product Liability Case

Atlantic City, N.J. state court verdict clears Merck of allegations the drug maker failed to warn patients of risks associated with the use of Vioxx.

Related Content

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel